Cognitive-Behavioral Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in College Students - Study 1 (ADHD)
Refinement and Testing of a New Cognitive-Behavioral Intervention to Treat Executive Dysfunction in College Students With Attention Deficit Hyperactivity Disorder (ADHD)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Sarah O'Neill, Ph.D.
- Phone Number: 212-650-5701
- Email: soneill2@ccny.cuny.edu
Study Contact Backup
- Name: Zeina Kamareddine, M.A.
- Phone Number: 212-650-7427
- Email: zkamare000@citymail.cuny.edu
Study Locations
-
-
New York
-
New York, New York, United States, 10031
- City College of New York
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Student at The City College of New York
- Diagnosis of ADHD, Inattentive or Combined Subtype
- In good physical health
Exclusion Criteria:
- Actively abusing drugs or alcohol within the past 6 months
- Actively suicidal
- Diagnosis of borderline personality disorder
- Diagnosis of bipolar disorder
- Diagnosis of a psychotic disorder
- Neurological disorder (such as traumatic brain injury, brain tumor, Parkinson's)
- History of childhood abuse or trauma or psychiatric condition that prevents clear
- confirmation of the presence of ADHD in childhood
- Any other acute psychiatric condition (e.g. acute panic disorder, severe depression) with treatment needs that take precedence over ADHD.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Cognitive Behavioral Therapy delivered in a group format
Participating students will be assessed before and after the 12-week group Cognitive-Behavioral intervention to ascertain their response to the treatment.
|
The intervention is 12 weeks long, made up of one 2- hour session each week.
These sessions are designed to help the participants develop strategies to improve their executive functioning skills including self- care, time management and organizational skills.
These skills will also be applied to specific academic tasks such as note-taking during reading and lectures, organizing and conducting research, and writing papers.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from Baseline Adult Investigator Symptom Rating Scale (AISRS) at six months
Time Frame: Change from Baseline AISRS at six months
|
The AISRS is a structured diagnostic Interview, administered by one of the study investigators to assess for Adult ADHD.
Scores are reported on a scale from 0 to 27, with higher score being worse.
|
Change from Baseline AISRS at six months
|
|
Change from Baseline Behavior Rating Scale of Executive Function - Adult Version (BRIEF-A) at six months
Time Frame: Change from Baseline BRIEF-A at 6 months
|
The Meta-Cognitive Index of the BRIEF-A will be used to measure change in executive functions, including time-management, organization, and planning.
Scores are reported as percentiles from 0 to 99 with a higher score being worse.
|
Change from Baseline BRIEF-A at 6 months
|
|
Change from Baseline Learning and Study Strategies Inventory (LASSI) at six months
Time Frame: Change from Baseline LASSI at 6 months
|
The LASSI is a self-rating scale that measures student awareness and use of learning and study strategies on 10 scales related to skill, will, and self-regulation.
Scores are reported as percentiles from 0 to 99 with a higher score being better.
|
Change from Baseline LASSI at 6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Mary V. Solanto, Ph.D., Northwell Health
- Principal Investigator: Anthony Rostain, M.D., Cooper School of Medicine at Rowan University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 20-0013
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.